Anti-Bcl-2 antibody [Bcl2/100]

• Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-Bcl-2 antibody [Bcl2/100] (AB117115)

Flow cytometric analysis of Human peripheral whole blood labeling Bcl-2 with ab117115 at 1 µg/mL.

• Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-Bcl-2 antibody [Bcl2/100] (AB117115)

Flow cytometric analysis of Human peripheral whole blood labeling Bcl-2 with ab117115 at 1 µg/mL, showing the separation of human lymphocytes (red-filled) from neutrophil granulocytes (black-dashed).

• WB

Lab

Western blot - Anti-Bcl-2 antibody [Bcl2/100] (AB117115)

Lane 1 : Wild type HAP1 whole cell lysate (20 μg)
Lane 2 : BCL2 knockout HAP1 whole cell lysate (20 μg)
Lane 3 : HeLa whole cell lysate (20 μg)
Lane 4 : THP-1 whole cell lysate (20 μg)
Lanes 1 - 4 : Merged signal (red and green). Green - ab117115 observed at 26 kDa. Red - loading control, ab181602, observed at 37 kDa.

ab117115 was shown to specifically react with BCL2 when BCL2 knockout samples were used. Wild-type and BCL2 knockout samples were subjected to SDS-PAGE. ab117115 and ab181602 (Rabbit anti GAPDH loading control) were incubated overnight at 4°C at 1 ug/ml and 1/10000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye^® 800CW) preabsorbed ab216772 and Goat anti-Rabbit IgG H&L (IRDye^® 680RD) preabsorbed ab216777 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-Bcl-2 antibody [Bcl2/100] (ab117115)

Predicted band size: 26 kDa

Observed band size: 26 kDa

false

• WB

CiteAb

Western blot - Anti-Bcl-2 antibody [Bcl2/100] (AB117115)

Bcl-2 western blot using anti-Bcl-2 antibody [Bcl2/100] ab117115. Publication image and figure legend from Xu, G. & Dang, C., 2017, Cancer Cell Int, PubMed 29213215.

ab117115 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab117115 please see the product overview.

CMTM5 inhibits tumour growth and metastasis through regulating PI3K-AKT signalling. a The related proteins of PI3K/Akt pathway, including AKT, pAKT, PI3K p85 subunit, p21, cyclinD1, cyclinE, Bcl2, Bax, Bad, cleaved caspase 3, MMP2 and MMP9 in CMTM5 overexpressed Huh7 cells were examined by western blot. b The relative kinase activity of PI3K in CMTM5 overexpressed Huh7 cells were examined by PI3K kinase ELISA assay. c The proteins levels of AKT, pAKT and P85 in Huh7-CMTM5 cells after treatment of PI3K inhibitor LY294002 (10 μM). d–g Huh7-CMTM5 cells were treated with or without LY294002, Cell growth (d), cell apoptosis (e) and cell metastatic and invasion (f, g) were examined. h–j The expression of PI3K p85 and pAKT (Ser473) in 76 paired tumour and adjacent normal liver tissues were examined by IHC staining and scored from 0 to 9 as described in the method. The left plots (h) were representative results of IHC staining against indicated proteins. The right plots were the statistical analysis of the correlation of CMTM5 expression with p85 (i) and pAKT (j) in HCC tissues (Spearman correlation test). Data are shown as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, One-Way ANOVA with Dunnett's test

false